AnteoTech (ASX: ADO) has reported progress across both its advanced battery technologies and life sciences businesses during the December 2025 quarter, alongside a capital raise that extends its funding runway into calendar year 2026. The quarter focused on expanding the product sales pipeline and advancing joint development partnerships intended to open new markets and accelerate commercialisation. AnteoTech said the $3.5 million equity raise completed in January provides the financial capacity to convert existing trials and partnerships into revenue-generating outcomes. The company also secured new AnteoBind sales with Japanese customers worth approximately $70,000, reflecting increased market awareness following execution of its June 2025 strategy. “We now have two sales and marketing personnel in Brisbane and are using more structured sales processes,” Ms Gray said.